Across two divisions – analytical services and diagnostics – Proteomics provides a range of services on a fee-for-service basis, including:
- Pharmacokinetic Testing
- Biosimilars/Biologics Drug Characterisation
- Proteome Mapping
- Protein Quantitation
- Targeted Mass Spectrometry
- Protein ID by Mass Spectrometry
- Post-translational Modifications (PTMs)
In addition to the Perkins, Proteomics International provides services to groups throughout the Indo-Asian region, with offices in India, Japan and Singapore. For pricing and ordering, please see the Proteomics International website.
Proteomics International’s diagnostics development is made possible by the company’s proprietary biomarker discovery platform called Promarker™, which seeks out protein ‘fingerprints’ in a sample. This disruptive technology enables the identification of proteins that differentiate between individuals with a disease and those without, utilising a simple blood test. The Promarker™ platform employs mass spectrometry-based technology to pinpoint the proteins serving as ‘fingerprints’ for various diseases or conditions.
It is a powerful alternative to genetic testing. The technology is so versatile it can be used to identify fingerprints across diverse biological sources, ranging from wheat seeds to human serum. Previously, the Promarker™ platform was utilised to develop PromarkerD, a world-first predictive test for diabetic kidney disease, that is currently being commercialised.
Biomarker discovery, verification and analytical validation is available as a fee for service model, or through a collaborative partnership with Proteomics International. Read more on our website and/or email us if you have any enquiries.
Proteomics International is using this platform to develop PromarkerEndo, the world’s first non-invasive diagnostic test for endometriosis, and PromarkerEso, a non-invasive test for the diagnosis of oesophageal adenocarcinoma and its pre-malignant condition, Barrett’s Oesophagus. In addition to others including asthma and COPD, diabetic retinopathy and oxidative stress. View our Promarker™ Pipeline here.
Diabetic kidney disease (DKD) is a serious complication arising from diabetes which if unchecked can lead to dialysis or kidney transplant. PromarkerD is a prognostic test that can predict future kidney function decline in patients with type 2 diabetes and no existing DKD. The patented PromarkerD test system uses a simple blood test to detect a unique ‘fingerprint’ of the early onset of the disease by measuring three serum protein biomarkers, combined with three routinely available conventional clinical variables (age, HDLcholesterol and estimated glomerular filtration rate (eGFR)). A cloud-based algorithm integrates the results into a patient risk report. In clinical studies published in leading journals PromarkerD correctly predicted up to 86% of otherwise healthy diabetics who went on to develop diabetic kidney disease within four years.
Further information is available through the PromarkerD web portal.
Visit the PromarkerD virtual booth here.
Proteomics International was established in 2001, and now has over two decades of experience in providing specialised analytical services built around proteomics-based technology.
Proteomics International is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International’s mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.
